Latest Altimmune News & Updates

See the latest news and media coverage for Altimmune. We track all announcements, press releases, and industry mentions in real time, all in one place.

Altimmune

Late-stage biopharmaceutical company developing therapeutics to treat serious liver disease

altimmune.com

Headquarters: Gaithersburg, United States
Founded year: 1997
Company type: Public company
Number of employees: 10–90
Industry: Pharmaceuticals

Last updated Today

Latest news about Altimmune

In short: Altimmune initiated a Phase 3 MASH trial and reported positive Phase 2 data for its alcohol use disorder candidate, pemvidutide.

Company announcements

August 12 Altimmune

Altimmune reports Q2 2026 results and business update

The company initiated a Phase 3 MASH trial, reported positive AUD trial data, completed ALD trial enrollment, and holds $519 million in cash.

August 3 Altimmune

Altimmune initiates PERFORMA Phase 3 trial of pemvidutide

The global registrational study evaluates pemvidutide in MASH patients with moderate to advanced fibrosis, following positive Phase 2b data. Topline data expected in 2029.

July 28 Altimmune

Altimmune announces positive RECLAIM Phase 2 trial results

Pemvidutide met its primary endpoint of reducing heavy drinking days and showed favorable tolerability.

June 2 Altimmune

Altimmune announces positive pemvidutide data at EASL 2026

New analyses show concurrent improvements in NITs and qFibrosis regression at 24 weeks.

Media coverage

August 24 Nikkei Biotech Online

US Altimmune's glucagon/GLP-1 receptor dual agonist significantly improves drinking behavior in phase 2 targeting alcohol use disorder

US Altimmune, a company specializing in the development of new drugs for chronic liver disease, announced on July 28, 2026, that it has met its primary endpoint in a phase 2 clinical trial (RECLAIM trial) targeting alcohol use disorder (AUD) with pemvidutide, a glucagon/glucagon-like peptide-1 (GLP-1) receptor dual agonist...

August 12 Kalkine Media

Altimmune (NASDAQ:ALT): What Does the Latest Update Mean for Trial Execution?

Current company-specific hook: its quarterly update renewed attention on metabolic-disease drug development. The central reader questions concern trial execution and clinical differentiation and cash ...

August 11 Kalkine Media

Altimmune (NASDAQ:ALT): What Could Today's clinical evidence and program focus Update Reveal?

Todays company update puts clinical evidence and program focus under a fresh disclosure lens Altimmune (NASDAQ:ALT) Healthcare Altimmune Inc (NASDAQ:ALT) 3.00 USD -0.050 ↓ 1.639...

August 5 Yahoo Finance

Kodiak s Q2 Loss Wider Than Expected, Pipeline Development in Focus

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical...

Never miss news about Altimmune

Track Altimmune and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.